# **PHAGE FUTURES**

## OCTOBER 25 2023 **Digital Summit** phagefuturesdigital.com

The leading platform accelerating the translation of bacteriophages into clinically and commercially viable and tangible commercial solutions

## **B**

## CONNECT

Take advantage of Q&As to ask our speakers your burning questions. Use our online networking platform to maximize your productivity. This event attracts the entire ecosystem of phage from leading biotech and pharma, to investors and academics making this an incredible opportunity to connect.

## LEARN

We're uniting leading phage companies and stakeholders from across the world, giving a more comprehensive insight into the latest clinical trial data than ever before. Whether your interests lie in science, research, healthcare, agriculture, or drug development there is a session for you.

## Summit Partners:



PHAGE CDMO

www.phagefuturesdigital.com



## **ENJOY**

More people than ever will have access to the event, bringing together more diverse perspectives and content and networking opportunities, and allowing for a broader outlook on the landscape of phage therapy.

RESERVE

YOUR

**FREE PASS** 

TODAY







## WELCOME

Join us online at Phage Futures Global Digital Summit 2023

We have created a virtual stage upon which to initiate allimportant discussions and forge partnerships between key stakeholders worldwide. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies and beyond.

Discover how you can be at the forefront of the developing phage therapy market.

Network and learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations, and regulatory bodies.

Summit Partners:



PHAGE CDMO

www.phagefuturesdigital.com

## Key topics to hear and participate in:

### **Clinical Trials**

Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic and acute illness

### Regulation

Insights and discussions between international governing bodies with regionspecific follow up conversations with the experts

### Latest Data

The latest clinical data from the leading pharma and biotech companies developing phage therapeutics

### Investment

Expert advice on how to find and secure financial investments, navigating the current investment landscape and future-proofing your organisation



 $\sim$ 



ch

## MEET OUR INDUSTRY LEADING SPEAKERS



Robert McKee **Principal Scientist** Locus Biosciences



Iddo Weiner Vice President of Research **BiomX** 



Greg German Co-Founder Phage Canada



Kristin Wannerberger Director and R&D Alliance Manager Ferring Pharmaceuticals



Jiayi Zhang Founder & Chief Executive Officer Phage CDMO



Matjaz Peterka Chief Executive Officer COBIK

## Summit Partners:



## PHAGE CDMO

www.phagefuturesdigital.com



Danish Malik Senior Lecturer Loughborough University



Mina Pastagia Chief Medical Officer



Barbara Hubad Chief Operating Officer JAFRAL



Diane Shader Smith Author & Cystic Fibrosis Advote

events@kisacoresearch.com



+44 (0) 203 696 2920



## MEET OUR INDUSTRY LEADING SPEAKERS



Justyna Kowalska Head of Product Management Proteon Pharmaceuticals



Tobi Nagel Founder & President Phages for Global Health



Carly Levine Associate AMR Action Fund



Clara Leandro Head of Infection Technophage



Matthew Tebeau Chief Operating Officer Phagelux

## Summit Partners:



PHAGE CDMO

www.phagefuturesdigital.com



Joseph Campbell Research Resources Project Officer NIH



Carrie-Lynn Furr Co-Founder & Chief Executive Officer





PLAN	YOUR DAY			
ESTBST6:00am11:00am6:10am11:10am		6.50am 7:10am		<ul> <li>Globally effective, off-the-shelf phage products for agriculture application – results from the trials across the world.</li> <li>The successful application of bacteriophages in poultry production, specifically in the prevention of Salmonella and E. coli infections</li> <li>Insights into Proteon studies and commercial application results from farms across the world, showcasing efficacy of products against diverse global strains</li> <li>Understanding the exceptional stability and off-the-shelf readiness of phage solutions</li> </ul> Justyna Kowalska, Head of Product Management, Proteon Pharmaceuticals From Discovery to Manufacturing: Fully integrated solutions for phage product development
6:30am 11:30 ar	<ul> <li>Scalable phage manufacturing using process analytical technologies to improve production</li> <li>Use of on-line sensors for Upstream (USP) production of phages in stirred-tank bioreactors</li> <li>Modelling and optimisation of USP phage production</li> <li>Downstream Processing of phages using Tangential Flow Filtration and Chromatography - Using MALDI-ToF, MADLS and other analytical approaches for phage drug substance characterisation and linking critical process parameters (CPP) with critical quality attributes (CQA)</li> <li>Danish Malik, Senior Lecturer, Loughborough University</li> </ul>	<b>7:30am</b> 8:30am	12:30pm 1:30pm	Jiayi Zhang, Founder & Chief Executive Officer, Phage CDMO Break Philanthropy, physicians, & phages pick up the phone! Describes the barriers and opportunities to bringing Phage Therapy to Physician Sketch the philanthropy landscape for phage therapy Share how Canada is one positive example of Physician and Philanthropic engagement Greg German, Co-Founder, Phage Canada
Summit Partners:	<b>VALUATE: VALUATE: VALUATE: VALUATE: VALUATE: VALUAT: </b>	ligital.com	٠	+44 (0) 203 696 2920 • events@kisacoresearch.com





ch

PLAN	YOUR DAY		
EST BST 8:50am 1:50pm 9:10am 2:10pm 9:30am 2:30 am	Manufacturing Perspective: From 1 phage to routine production of highly pure 1E16 phages for GMP or non-GMP use Barbara Hubad, Chief Operating Officer, JAFRAL Armata Pharmaceuticals clinical trials overview for acute and chronic infections with systemic and local phage administration Mina Pastagia, Chief Medical Officer, Armata Pharmaceuticals Results from phase 1b/2a randomized, double-blind, placebo controlled	10:50am 3:50pm 11:10am 4:10pm	<ul> <li>Efficacy study of bacteriophage COP-80B for treatment of S. epidermidis prosthetic joint infection in mouse</li> <li>In vitro and in silico bacteriophage COP-80B characterization</li> <li>Development of mice model (implant optimization, surgery protocol, etc)</li> <li>Pharmacokinetics and pharmacodynamic of COP-80B in mice model</li> <li>Efficacy of COP-80B for treatment of prosthetic joint infection in mice model and comparison with antibiotic treatment (preliminary)</li> <li>Matjaz Peterka, Chief Executive Officer, COBIK</li> <li>Overcoming challenges and exploring opportunities in bacteriophage manufacturing</li> </ul>
9:50am         2:50pm           10:30am         3:30pm	study. Iddo Weiner, Vice President of Research, BiomX Break The Beast Within: prophage challenges in manufacturing host selection • The removal of prophages in hosts for use in phage manufacturing Robert McKee, Principal Scientist, Locus Biosciences	11:30am       4:30pm	Clara Leandro, Head of Infection, Technophage Break
Summit Partners:	<b>VALUATE: VALUATE: VALUATE: VALUATE: VALUATE: VALUAT: </b>	igital.com •	+44 (0) 203 696 2920 • events@kisacoresearch.com

PL	AN	YOUR DAY				
EST 8:50am 9:10am	BST 1:50pm 2:10pm	Manufacturing Perspective: From 1 phage to routine production of highly pure 1E16 phages for GMP or non-GMP use Barbara Hubad, Chief Operating Officer, JAFRAL Armata Pharmaceuticals clinical trials overview for acute and chronic infections with systemic and local phage administration Mina Pastagia, Chief Medical Officer, Armata Pharmaceuticals	10:50am	3:50pm	<ul> <li>Efficacy study of bacteriophage COP-80B for treatment of S. epidermidis prosthetic joint infection in mouse</li> <li>In vitro and in silico bacteriophage COP-80B characterization</li> <li>Development of mice model (implant optimization, surgery protocol, etc)</li> <li>Pharmacokinetics and pharmacodynamic of COP-80B in mice model</li> <li>Efficacy of COP-80B for treatment of prosthetic joint infection in mice model and comparison with antibiotic treatment (preliminary)</li> </ul> Matjaz Peterka, Chief Executive Officer, COBIK	
9:30am	2:30 am	Results from phase 1b/2a randomized, double-blind, placebo controlled study. Iddo Weiner, Vice President of Research, BiomX	11:10am 11:30am		Overcoming challenges and exploring opportunities in bacteriophage manufacturing Clara Leandro, Head of Infection, Technophage Break	
9:50am 10:30am	2:50pm 3:30pm	Break         The Beast Within: prophage challenges in manufacturing host selection         • The removal of prophages in hosts for use in phage manufacturing         Robert McKee, Principal Scientist, Locus Biosciences				
Summit Part	iners:	<b>DAFRAL</b> passion for biosolutions <b>PHAGE CDMO</b> www.phagefuturesdi	igital.com	•	+44 (0) 203 696 2920 • events@kisacoresearch.com	rct





## PLAN YOUR DAY

/	EST	BST	
	12:00pm	5:00pm	<ul> <li>An International Consortium Drafting Guidelines for Phage Banks to Understand the global economics of bacteriophage application</li> <li>Drafting guidance documents on the scientific requirements for maintaining phage banks that could be used for therapy</li> <li>Establishing standards for phage characterization and storage to expedite transfer of phages during emergencies</li> <li>More than 60 experts from over 20 countries are currently working on these guidelines</li> </ul>
			Tobi Nagel, Founder & President, Phages for Global Health
	12:20pm	5:20pm	<ul> <li>Funding: How to build a good business model and attract investment</li> <li>How to build an innovative phage pipeline that will draw investment</li> <li>Explore how to build a good business model and interact successfully with investors</li> <li>Know how investors direct their funding and resources in the phage industry</li> </ul>
			Joseph Campbell, Research Resources Project Officer, NIH Carly Levine, Associate, AMR Action Fund
			"Phage Futures is biology, phage the year!"

Summit Partners:



PHAGE CDMO

www.phagefuturesdigital.com

### 12:40pm 5:40pm Salt in My Soul: An unfinished life

Mallory Smith passed away from a superbug at the age of 25, two months after she received a double lung transplant. As she was dying, her father moved mountains to get an experimental treatment called phage therapy for her; a treatment that had been used 100 years ago before penicillin was discovered. Once it was, penicillin's patent protection and financial incentives rendered work on phage therapy obsolete. The United States Navy responded to Mallory's story and provided the phage therapy cocktail that Mallory received. Tragically, it didn't arrive in time to save her, but the autopsy revealed that it had started to work – and would have saved her life if she had gotten it earlier. Diane Shader Smith shares this riveting story about mobilizing the medical community and the power each of us has to make a difference.

Diane Shader Smith, Author and Cystic Fibrosis Advocate



s my favourite conference of the year! The who's who of fundamental phage nerapy, and regulatory show up in force, and I always learn new things every

LOCUS BIOSCIENCES









## THANKS TO OUR PARTNERS

### SUMMIT PARTNER

## PHAGE CDMO

### PHAGE CDMO

PHAGE CDMO is a contract development and manufacturing company specializing in bacteriophage production. Our manufacturing site is strategically located in Hangzhou - the manufacturing hub in China.

PHAGE CDMO offers both non-GMP (up to 1000L) and cGMP (clinical materials up to 30L) production facilities to meet the demands of various applications of phage products. Our areas of expertise include therapeutics, food and agriculture, veterinary, diagnostics, and bioprocessing raw materials.



## JAFRAL

JAFARAL is world's leading CMO for production of bacteriophages, because it's has more than 10 years' experience in manufacturing of phages, other biologics production, large scale production and knowing GMP guidelines. Likewise, JAFRAL has all these years also been involved in plasmid DNA and recombinant proteins production at various levels.

JAFRAL's custom development and manufacturing services have helped developers across the globe to accelerate research and open up their laboratories for groundbreaking science and breakthrough discoveries.

Summit Partners:



PHAGE CDMO

www.phagefuturesdigital.com

### SUMMIT PARTNER

JAFRAL assion for biosolutions

## WANT TO SEE YOUR LOGO HERE?

Find out more about how you can support Phage Futures and benefit from our partnership opportunities.



+44 (0) 203 696 2920 events@kisacoresearch.com



## PARTNERSHIP OPPORTUNITIES

Be the answer to the industry's questions by showcasing your company in a new light. Raise your profile and form new partnerships with more opportunities for meaningful interactions.

## Why Partner with us?

- ✓ Be recognised as an industry leader
- ✓ Get the eyes of hundreds of decision-makers on your brand
- Create space for the most important conversations, and the ones you never knew were out there
- ✓ Fuel your pipeline for 2024 and beyond
- ✓ Network with the industry elite
- Amplify your biggest announcements, research, and expertise

Summit Partners:



PHAGE CDMO

www.phagefuturesdigital.com

## GET IN TOUCH

Want to know more? We're here to help you find out all about our sponsorship options including:

THOUGHT LEADERSHIP Presentations, Panel Discussions and Workshops

NETWORKING

1-1 Meetings, Digital Boardrooms, Online Networking Platform

BRAND AWARENESS

Marketing Campaigns, Advertising, Presentations, Content and Resources





James Tappenden Commercial Partnerships Director James.tappenden@kisacoresearch.com







## READY TO REGISTER? BOOK YOUR FREE TICKET TODAY

In 2023 we are thrilled to be reuniting the Phage Futures community, providing a space where phage researchers, from across the globe, can connect. We are committed to making Phage Futures as accessible as possible.

For this reason, the summit will be run digitally, free to attend, and open to all. If you'd like to support the summit, contribute to the program, and engage with our community, please email partner@kisacoresearch.com for more information on our sponsorship opportunities.

To secure your place at the summit and to access the digital platform, register for your free pass today!

## **REGISTER NOW**

Summit Partners:



PHAGE CDMO

www.phagefuturesdigital.com

This is a really superb meeting. It's so well run, and the lineup is always very exciting! It's a huge pleasure and very beneficial in all sorts of ways. Highly recommended!

Cellexus

"Phage Futures was great for learning about novel phage research and networking with big players in the phage world."

Yale University

"Phage Futures connects both industry and academia such that research can be scaled to greater heights for better accessible patient care. Networking with so many industry experts was a huge benefit for me and I would highly recommend attending Phage Futures in the future"

University of Warick

"Phage Futures endeavours every year to put together an extraordinary program encompassing the most recent advances in the clinical application of bacteriophages and commercially viable non-traditional therapeutics."

PhageLux



